OR WAIT null SECS
Under an expanded agreement with J&J, Catalent Biologics will increase manufacturing capacity at its Anagni, Italy, site to accommodate the large-scale commercial supply of Janssen’s COVID-19 vaccine.
Catalent announced on March 17, 2021 that it has expanded its partnership with Janssen Pharmaceutica NV and Janssen Pharmaceuticals, two of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which Catalent Biologics will increase manufacturing capacity at its Anagni, Italy, site to accommodate the large-scale commercial supply of Janssen’s COVID-19 vaccine.
Under the terms of the expanded agreement, which also includes vial-filling, inspection, labeling, and packaging services, Catalent will fast-track the qualification and scale-up of an additional high-speed vial-filling line that is set to be operational in the fourth quarter of 2021 to support vaccine production through late 2022, Catalent said in a company press release.
“We are pleased to expand our partnership with Janssen to support demand of its COVID-19 vaccine in Europe,” said Mario Gargiulo, president, Catalent Biologics, Europe, in the press release. “Our global network of state-of-the-art biologics facilities, combined with our deep expertise in manufacturing scale-up and commercial launch, is well-suited to help provide a solution to this public health crisis.”